Marta Lustig

Kiel, SH 24105, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Fc-Silenced CD89 × EGFR Bispecific Antibodies Promote Neutrophil and Macrophage Antitumor Activity.

Fc-Silenced CD89 × EGFR Bispecific Antibodies Promote Neutrophil and Macrophage Antitumor Activity.

Journal: Antibodies (Basel, Switzerland)

Published: May 22, 2026

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 13, 2026

Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.

Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.

Journal: EMBO molecular medicine

Published: November 19, 2025

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays.

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays.

Journal: Frontiers in immunology

Published: November 04, 2025

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Journal: Blood neoplasia

Published: September 24, 2025

Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes.

Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes.

Journal: Frontiers in oncology

Published: August 30, 2024

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.

Journal: PNAS nexus

Published: July 11, 2024

Antibody-lectin chimeras for glyco-immune checkpoint blockade.

Antibody-lectin chimeras for glyco-immune checkpoint blockade.

Journal: Nature biotechnology

Published: April 18, 2024

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.

Journal: Cancers

Published: June 03, 2023

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.

Journal: Nature communications

Published: April 07, 2023

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.

Journal: Frontiers in immunology

Published: March 03, 2023

Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?

Journal: Frontiers in immunology

Published: August 12, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026